Cited 31 time in
Ginsenoside Rh2 Suppresses Breast Cancer Cell Proliferation by Epigenetically Regulating the Long Noncoding RNA C3orf67-AS1
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Jeong, Dawoon | - |
| dc.contributor.author | Ham, Juyeon | - |
| dc.contributor.author | Park, Sungbin | - |
| dc.contributor.author | Kim, Hyeon Woo | - |
| dc.contributor.author | Kim, Heejoo | - |
| dc.contributor.author | Ji, Hwee Won | - |
| dc.contributor.author | Kim, Sun Jung | - |
| dc.date.accessioned | 2023-04-28T05:42:21Z | - |
| dc.date.available | 2023-04-28T05:42:21Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.issn | 0192-415X | - |
| dc.identifier.issn | 1793-6853 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/8609 | - |
| dc.description.abstract | Ginsenoside Rh2, a major bioactive ingredient abundant in red ginseng, has an antiproliferative effect on various cancer cells. In this study, we report a novel long noncoding RNA, C3orf67-AS1, which was identified as being hypermethylated at a CpG site of the promoter by Rh2 in MCF-7 cancer cells. Rh2-induced hypermethylation was responsible for the lower gene expression; the expression was recovered following treatment with a methyltransferase inhibitor, 5-aza-2'-deoxycytidine. When C3orf67-AS1 was downregulated by a siRNA, the cell growth rate was decreased, demonstrating the RNA's oncogenic activity. Accordingly, breast cancer patients showed a lower methylation and higher expression level of C3orf67-AS1. Within 800 kb flanking C3orf67-AS1 on the chromosome, eight genes were found, and four genes including C3orf67 (the sense strand gene of C3orf67-AS1) were downregulated by Rh2. In particular, C3orf67 was downregulated when C3orf67-AS1 was suppressed by a siRNA; however, the expression of C3orf67-AS1 was not affected by C3orf67. Taken together, this study identifies a novel noncoding RNA, C3orf67-AS1, of which the expression could be suppressed by Rh2 via promoter methylation, thereby mediating the anti-proliferative effect of the ginsenoside. | - |
| dc.format.extent | 16 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | WORLD SCIENTIFIC PUBL CO PTE LTD | - |
| dc.title | Ginsenoside Rh2 Suppresses Breast Cancer Cell Proliferation by Epigenetically Regulating the Long Noncoding RNA C3orf67-AS1 | - |
| dc.type | Article | - |
| dc.publisher.location | 싱가폴 | - |
| dc.identifier.doi | 10.1142/S0192415X19500848 | - |
| dc.identifier.scopusid | 2-s2.0-85074161277 | - |
| dc.identifier.wosid | 000498813900012 | - |
| dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CHINESE MEDICINE, v.47, no.7, pp 1643 - 1658 | - |
| dc.citation.title | AMERICAN JOURNAL OF CHINESE MEDICINE | - |
| dc.citation.volume | 47 | - |
| dc.citation.number | 7 | - |
| dc.citation.startPage | 1643 | - |
| dc.citation.endPage | 1658 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Integrative & Complementary Medicine | - |
| dc.relation.journalResearchArea | General & Internal Medicine | - |
| dc.relation.journalWebOfScienceCategory | Integrative & Complementary Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
| dc.subject.keywordPlus | OCCUPANCY | - |
| dc.subject.keywordPlus | PATHWAY | - |
| dc.subject.keywordPlus | RG3 | - |
| dc.subject.keywordAuthor | CpG Methylation | - |
| dc.subject.keywordAuthor | Ginsenoside Rh2 | - |
| dc.subject.keywordAuthor | Long Noncoding RNA | - |
| dc.subject.keywordAuthor | MCF-7 | - |
| dc.subject.keywordAuthor | Breast Cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
